

### Remarks

As noted above, the claims have been amended as requested by the Examiner. In particular, the preamble of claims 33-37, 67-71, 92-96, 126-130, 161-165, and 177-181 has been amended to recite "labeled antibody." Applicants note that this amendment is merely cosmetic, and does not affect the scope of the claims. Similarly, claims 30-31, 54, 89-90, 113, 124, 140-141, 158-159, and 174-175 have been amended to replace the term "which" with the phrase "wherein the antibody." Applicants note that these amendments are also merely cosmetic, and do not affect the scope of the claims. Indeed, the Examiner confirmed during the teleconference that these amendments do not exclude antibody fragments from the scope of the amended claims.

Claims 21-25, 28-51, 54-60, 63-84, 87-110, 113-119, and 122-198 are pending. Claims 21-25, 28-29, 32, 38-40, 42-43, 56-60, 63-64, 66, 72-74, 76-77, 80-84, 87-88, 91, 97-99, 101-102, 115-119, 122-123, 125, 131-133, 135-136, 139, 142-157, 160, 166-173, 176, 182-188, and 194-198 have been allowed. Claims 45-46, 79, 104-105, and 138 have been withdrawn; however, Applicants note that these withdrawn method of use claims depend from allowed claims 23, 58, 82, and 117. Accordingly, pursuant to M.P.E.P. § 821.04 at 800-63 and as requested in the response filed August 4, 2003, Applicants respectfully request that the Examiner rejoin claims 45-46, 79, 104-105, and 138, and indicate the allowance of such claims in the next action.

Further, the Examiner indicated during the teleconference that claims 30-31, 33-37, 54, 67-71, 89-90, 92-96, 113, 124, 126-130, 140-141, 158-159, 161-165, 174-175, and 177-181 would also be allowed with the current amendments, and that the previous response overcame the remainder of the objections and rejections. Accordingly, Applicants believe that all pending claims are in form for allowance.


### Conclusion

Applicants respectfully request that the above-made remarks and amendments be entered and made of record in the file history of the instant application. In view of the foregoing remarks, Applicants believe that this application is now in condition for allowance, and an early notice to that effect is urged. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicants would expedite the allowance of this application. If there are any fees due in connection

with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425.  
If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: April 16, 2004

Respectfully submitted,

By   
Mark J. Hyman  
Registration No.: 46,789  
HUMAN GENOME SCIENCES, INC.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(240) 314-1224


MJP/MJH/KC/lcc

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8

1. Fax Cover
2. Amendment Under 37 C.F.R. § 1.111

I hereby certify that the above-listed correspondence is being facsimile transmitted to the United States Patent and Trademark Office on April 16, 2004.

Respectfully submitted,

By   
Mark J. Hyman  
Registration No.: 46,789  
HUMAN GENOME SCIENCES, INC.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(240) 314-1224